Copyright Reports & Markets. All rights reserved.

Global Transthyretin (TTR) Stabilizer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Transthyretin (TTR) Stabilizer Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Tafamidis
    • 1.3.3 Acoramidis
  • 1.4 Market Analysis by Product Attributes
    • 1.4.1 Overview: Global Transthyretin (TTR) Stabilizer Consumption Value by Product Attributes: 2021 Versus 2025 Versus 2032
    • 1.4.2 Originator
    • 1.4.3 Generic Products
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global Transthyretin (TTR) Stabilizer Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 ATTR-CM
    • 1.5.3 ATTR-PN
  • 1.6 Global Transthyretin (TTR) Stabilizer Market Size & Forecast
    • 1.6.1 Global Transthyretin (TTR) Stabilizer Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global Transthyretin (TTR) Stabilizer Sales Quantity (2021-2032)
    • 1.6.3 Global Transthyretin (TTR) Stabilizer Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Transthyretin (TTR) Stabilizer Product and Services
    • 2.1.4 Pfizer Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 BridgeBio Pharma
    • 2.2.1 BridgeBio Pharma Details
    • 2.2.2 BridgeBio Pharma Major Business
    • 2.2.3 BridgeBio Pharma Transthyretin (TTR) Stabilizer Product and Services
    • 2.2.4 BridgeBio Pharma Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 BridgeBio Pharma Recent Developments/Updates
  • 2.3 Bayer AG
    • 2.3.1 Bayer AG Details
    • 2.3.2 Bayer AG Major Business
    • 2.3.3 Bayer AG Transthyretin (TTR) Stabilizer Product and Services
    • 2.3.4 Bayer AG Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Bayer AG Recent Developments/Updates
  • 2.4 Laboratorios Bagó S.A.
    • 2.4.1 Laboratorios Bagó S.A. Details
    • 2.4.2 Laboratorios Bagó S.A. Major Business
    • 2.4.3 Laboratorios Bagó S.A. Transthyretin (TTR) Stabilizer Product and Services
    • 2.4.4 Laboratorios Bagó S.A. Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Laboratorios Bagó S.A. Recent Developments/Updates
  • 2.5 Qilu Pharmaceutical Co., Ltd
    • 2.5.1 Qilu Pharmaceutical Co., Ltd Details
    • 2.5.2 Qilu Pharmaceutical Co., Ltd Major Business
    • 2.5.3 Qilu Pharmaceutical Co., Ltd Transthyretin (TTR) Stabilizer Product and Services
    • 2.5.4 Qilu Pharmaceutical Co., Ltd Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Qilu Pharmaceutical Co., Ltd Recent Developments/Updates
  • 2.6 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd
    • 2.6.1 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd Details
    • 2.6.2 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd Major Business
    • 2.6.3 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd Transthyretin (TTR) Stabilizer Product and Services
    • 2.6.4 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd Recent Developments/Updates
  • 2.7 Shijiazhuang Keren Pharmaceutical Technology Co., Ltd
    • 2.7.1 Shijiazhuang Keren Pharmaceutical Technology Co., Ltd Details
    • 2.7.2 Shijiazhuang Keren Pharmaceutical Technology Co., Ltd Major Business
    • 2.7.3 Shijiazhuang Keren Pharmaceutical Technology Co., Ltd Transthyretin (TTR) Stabilizer Product and Services
    • 2.7.4 Shijiazhuang Keren Pharmaceutical Technology Co., Ltd Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Shijiazhuang Keren Pharmaceutical Technology Co., Ltd Recent Developments/Updates
  • 2.8 Tuteur S.A.C.I.F.I.A.
    • 2.8.1 Tuteur S.A.C.I.F.I.A. Details
    • 2.8.2 Tuteur S.A.C.I.F.I.A. Major Business
    • 2.8.3 Tuteur S.A.C.I.F.I.A. Transthyretin (TTR) Stabilizer Product and Services
    • 2.8.4 Tuteur S.A.C.I.F.I.A. Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Tuteur S.A.C.I.F.I.A. Recent Developments/Updates
  • 2.9 Adium Pharma / Laboratorios Monte Verde
    • 2.9.1 Adium Pharma / Laboratorios Monte Verde Details
    • 2.9.2 Adium Pharma / Laboratorios Monte Verde Major Business
    • 2.9.3 Adium Pharma / Laboratorios Monte Verde Transthyretin (TTR) Stabilizer Product and Services
    • 2.9.4 Adium Pharma / Laboratorios Monte Verde Transthyretin (TTR) Stabilizer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Adium Pharma / Laboratorios Monte Verde Recent Developments/Updates

3 Competitive Environment: Transthyretin (TTR) Stabilizer by Manufacturer

  • 3.1 Global Transthyretin (TTR) Stabilizer Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Transthyretin (TTR) Stabilizer Revenue by Manufacturer (2021-2026)
  • 3.3 Global Transthyretin (TTR) Stabilizer Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Transthyretin (TTR) Stabilizer by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Transthyretin (TTR) Stabilizer Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Transthyretin (TTR) Stabilizer Manufacturer Market Share in 2025
  • 3.5 Transthyretin (TTR) Stabilizer Market: Overall Company Footprint Analysis
    • 3.5.1 Transthyretin (TTR) Stabilizer Market: Region Footprint
    • 3.5.2 Transthyretin (TTR) Stabilizer Market: Company Product Type Footprint
    • 3.5.3 Transthyretin (TTR) Stabilizer Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Transthyretin (TTR) Stabilizer Market Size by Region
    • 4.1.1 Global Transthyretin (TTR) Stabilizer Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Transthyretin (TTR) Stabilizer Consumption Value by Region (2021-2032)
    • 4.1.3 Global Transthyretin (TTR) Stabilizer Average Price by Region (2021-2032)
  • 4.2 North America Transthyretin (TTR) Stabilizer Consumption Value (2021-2032)
  • 4.3 Europe Transthyretin (TTR) Stabilizer Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Transthyretin (TTR) Stabilizer Consumption Value (2021-2032)
  • 4.5 South America Transthyretin (TTR) Stabilizer Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Transthyretin (TTR) Stabilizer Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Transthyretin (TTR) Stabilizer Sales Quantity by Type (2021-2032)
  • 5.2 Global Transthyretin (TTR) Stabilizer Consumption Value by Type (2021-2032)
  • 5.3 Global Transthyretin (TTR) Stabilizer Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Transthyretin (TTR) Stabilizer Sales Quantity by Application (2021-2032)
  • 6.2 Global Transthyretin (TTR) Stabilizer Consumption Value by Application (2021-2032)
  • 6.3 Global Transthyretin (TTR) Stabilizer Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Transthyretin (TTR) Stabilizer Sales Quantity by Type (2021-2032)
  • 7.2 North America Transthyretin (TTR) Stabilizer Sales Quantity by Application (2021-2032)
  • 7.3 North America Transthyretin (TTR) Stabilizer Market Size by Country
    • 7.3.1 North America Transthyretin (TTR) Stabilizer Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Transthyretin (TTR) Stabilizer Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Transthyretin (TTR) Stabilizer Sales Quantity by Type (2021-2032)
  • 8.2 Europe Transthyretin (TTR) Stabilizer Sales Quantity by Application (2021-2032)
  • 8.3 Europe Transthyretin (TTR) Stabilizer Market Size by Country
    • 8.3.1 Europe Transthyretin (TTR) Stabilizer Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Transthyretin (TTR) Stabilizer Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Transthyretin (TTR) Stabilizer Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Transthyretin (TTR) Stabilizer Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Transthyretin (TTR) Stabilizer Market Size by Region
    • 9.3.1 Asia-Pacific Transthyretin (TTR) Stabilizer Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Transthyretin (TTR) Stabilizer Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Transthyretin (TTR) Stabilizer Sales Quantity by Type (2021-2032)
  • 10.2 South America Transthyretin (TTR) Stabilizer Sales Quantity by Application (2021-2032)
  • 10.3 South America Transthyretin (TTR) Stabilizer Market Size by Country
    • 10.3.1 South America Transthyretin (TTR) Stabilizer Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Transthyretin (TTR) Stabilizer Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Transthyretin (TTR) Stabilizer Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Transthyretin (TTR) Stabilizer Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Transthyretin (TTR) Stabilizer Market Size by Country
    • 11.3.1 Middle East & Africa Transthyretin (TTR) Stabilizer Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Transthyretin (TTR) Stabilizer Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Transthyretin (TTR) Stabilizer Market Drivers
  • 12.2 Transthyretin (TTR) Stabilizer Market Restraints
  • 12.3 Transthyretin (TTR) Stabilizer Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Transthyretin (TTR) Stabilizer and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Transthyretin (TTR) Stabilizer
  • 13.3 Transthyretin (TTR) Stabilizer Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Transthyretin (TTR) Stabilizer Typical Distributors
  • 14.3 Transthyretin (TTR) Stabilizer Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Transthyretin (TTR) Stabilizer market size was valued at US$ 7017 million in 2025 and is forecast to a readjusted size of US$ 13027 million by 2032 with a CAGR of 7.6% during review period.
    TTR Stabilizers (Transthyretin Stabilizers) are a class of disease-modifying therapies that directly bind to transthyretin (TTR) and enhance the kinetic stability of its native tetrameric structure, thereby reducing TTR tetramer dissociation, protein misfolding, and subsequent amyloid fibril formation. Through this mechanism, TTR stabilizers can slow or improve the progression of transthyretin amyloidosis (ATTR).
    Compared with the broader category of TTR Modulators, TTR stabilizers do not suppress TTR production or gene expression. Instead, they act by stabilizing circulating TTR tetramers. Currently commercialized TTR stabilizers are primarily based on tafamidis and acoramidis, covering originator, branded, and selected generic products. Their main indications include ATTR-CM (Transthyretin Amyloid Cardiomyopathy) and ATTR-PN (Hereditary Transthyretin Amyloidosis with Polyneuropathy), with ATTR-CM currently representing the largest commercial segment and the principal source of incremental demand globally.
    According to our research, the global TTR Stabilizers market is transitioning from an early stage dominated by tafamidis as the primary therapeutic molecule toward a more diversified competitive structure characterized by continued tafamidis expansion, rapid commercialization of acoramidis, and the entry of regional generic products. As awareness of ATTR-CM increases, non-invasive diagnostic technologies become more widely adopted, patient screening expands, and reimbursement and insurance coverage improve across more countries, TTR stabilizers have become one of the largest and most established disease-modifying treatment classes for ATTR.
    From a product perspective, tafamidis continues to account for the majority of the global TTR stabilizers market, with Pfizer’s Vyndamax/Vyndaqel remaining the leading commercial franchise. At the same time, acoramidis has emerged as a new competitive pathway based on its high degree of TTR stabilization and demonstrated clinical benefits in ATTR-CM. BridgeBio’s Attruby and Bayer-commercialized BEYONTTRA are expanding across the United States, Europe, and other markets. Meanwhile, tafamidis generics and locally branded products have entered markets such as China and Argentina, shifting the competitive landscape from a largely single-originator structure toward a combination of originator tafamidis, next-generation acoramidis, and regional generic products.
    From a demand perspective, ATTR-CM has become the largest application segment and the primary growth driver for TTR stabilizers, supported by a larger addressable patient population, substantial room for further diagnosis-rate improvement, and strong demand for long-term oral therapy. ATTR-PN is comparatively more concentrated in historical and residual use of products such as tafamidis 20 mg in selected countries. Looking forward, the TTR stabilizers market is expected to continue benefiting from improved ATTR patient identification and treatment accessibility, while growth will also be influenced by internal switching from tafamidis to acoramidis, increasing tafamidis genericization, and the expansion of TTR silencers such as vutrisiran into ATTR-CM. Competition is therefore evolving from a market driven primarily by new patient additions toward one increasingly shaped by therapeutic efficacy, treatment convenience, reimbursement and affordability, and product share migration.
    Report Scope
    This report is a detailed and comprehensive analysis for global Transthyretin (TTR) Stabilizer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Transthyretin (TTR) Stabilizer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Transthyretin (TTR) Stabilizer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Transthyretin (TTR) Stabilizer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Transthyretin (TTR) Stabilizer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Transthyretin (TTR) Stabilizer
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Transthyretin (TTR) Stabilizer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, BridgeBio Pharma, Bayer AG, Laboratorios Bagó S.A., Qilu Pharmaceutical Co., Ltd, Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd, Shijiazhuang Keren Pharmaceutical Technology Co., Ltd, Tuteur S.A.C.I.F.I.A., Adium Pharma / Laboratorios Monte Verde, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Transthyretin (TTR) Stabilizer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market Segmentation
    Market segment by Type
    Tafamidis
    Acoramidis
    Market segment by Product Attributes
    Originator
    Generic Products
    Market segment by Application
    ATTR-CM
    ATTR-PN
    Major players covered
    Pfizer
    BridgeBio Pharma
    Bayer AG
    Laboratorios Bagó S.A.
    Qilu Pharmaceutical Co., Ltd
    Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd
    Shijiazhuang Keren Pharmaceutical Technology Co., Ltd
    Tuteur S.A.C.I.F.I.A.
    Adium Pharma / Laboratorios Monte Verde
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Transthyretin (TTR) Stabilizer product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Transthyretin (TTR) Stabilizer, with price, sales quantity, revenue, and global market share of Transthyretin (TTR) Stabilizer from 2021 to 2026.
    Chapter 3, the Transthyretin (TTR) Stabilizer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Transthyretin (TTR) Stabilizer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Transthyretin (TTR) Stabilizer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Transthyretin (TTR) Stabilizer.
    Chapter 14 and 15, to describe Transthyretin (TTR) Stabilizer sales channel, distributors, customers, research findings and conclusion.

    Buy now